'Why we do What we do in Cardiology'

1. The REDUCE-AMI trial showed no significant benefit of beta-blockers in reducing all-cause mortality or future myocardial infarction in patients with acute myocardial infarction and preserved left ventricular ejection fraction. 2. The trial included 5,020 patients who were randomized to either beta-blockade with metoprolol or bisoprolol or usual care, with follow-up over a median of 3.5 years. 3...

The HF-OPT study investigated the improvement of left ventricular ejection fraction (LVEF) beyond 90 days in patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF) . In this prospective, multicenter observational study, 1,300 patients with HFrEF (LVEF ≤35%) were initially enrolled. Participants wore a wearable cardioverter-defibrillator (WCD) and received guideline-dire...

Overview : This review discusses the use and future directions of AI in cardiology, focusing on areas like electrocardiography, telemetry and wearables, echocardiography, CMR, nuclear cardiology, CT, electrophysiology studies, coronary angiography, and genetics or multiomics. AI Glossary : Includes key terms such as algorithms, AUC, artificial intelligence, neural networks, classification, CNNs, d...

Collaborative vascular care is emphasized to address health disparities , gaps in medical therapy , structured exercise , and good foot care along with appropriate revascularization to prevent limb loss . The new guidelines update the 2016 guidelines and call for broad implementation of the Peripheral Artery Disease (PAD) National Action Plan to improve outcomes. Emphasis on rigorous medical thera...

2024 HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise Mavacamten : Class 1 recommendation for symptomatic obstructive HCM. Exercise : Now allows for "vigorous" activity; competitive level still limited. Pediatric Section : Separate guidelines with new risk-prediction tools. Atrial Fibrillation : Enhanced monitoring is recommended. Future Research : Needed on nonobstructive...

Key Points: Positive Aspects of DOACs: DOACs are acknowledged for their convenience, efficacy, and safety in conditions like atrial fibrillation (AF) and venous thromboembolism (VTE). The review supports their use in stroke prevention, AF, recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), valve disease (with exceptions), VTE management, cancer-associated thrombosis,...

Background: Traditional practice requires fasting before cardiac catheterization, but there's no evidence to support it. Objective: This study compared a heart-healthy pre-procedure diet with fasting to determine best practices. Methods: 197 patients were randomly assigned to either a heart-healthy diet or fasting before their cardiac catheterization. Results: Satisfaction: Patients on the hea...

Key Points In patients not taking antianginal meds, PCI alleviated some—but not all—symptoms Background: Percutaneous coronary intervention (PCI) is commonly used to alleviate stable angina symptoms. Uncertainty exists regarding whether PCI is more effective than a placebo procedure in patients not using antianginal medication. Methods: A double-blind, randomized, placebo-controlled PCI trial was...

Study: STRONG-HF trial examined rapid up-titration of heart failure medications (GDMT) after hospitalization. Goal: Reach optimal GDMT doses within 2 weeks after discharge. Findings: Over 90% of patients achieved medium-to-high GDMT doses within 2 weeks. Patients with lower blood pressure, more congestion, and higher risk markers received less up-titration. Higher GDMT doses: Associated with lower...

Key Points from "Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR": The study compares two strategies for managing LDL cholesterol in coronary artery disease (CAD): Treat-to-target: aiming for LDL levels between 50-70 mg/dL. High-intensity statin: prescribing the highest tolerated statin dose regardless of LDL level. Both strategies are equally effective in preve...

Key Points of the Study: T-TEER with the TriClip device significantly improved health status in patients with severe tricuspid regurgitation (TR) compared to medical therapy alone. This improvement was seen in both the short-term (1 month) and long-term (1 year) after the procedure. T-TEER patients were more likely to be alive and well (defined as good KCCQ score and no decline) at 1 year compared...

Key Points from PROMISE 2 Trial: • Problem: 20% of CLTI patients have no revascularization options, leading to amputations. • Solution: Transcatheter arterialization of deep veins creates an artery-to-vein connection, delivering oxygenated blood to the ischemic foot and potentially preventing amputation. • Study: Analyzed 105 patients with no other treatment options who underwent the procedure wit...

Key Points from this trial: The CLASP IID trial, the first randomized controlled trial comparing the PASCAL system and the MitraClip system in prohibitive-risk patients with significant symptomatic degenerative mitral regurgitation (DMR), aimed to report primary and secondary endpoints along with 1-year outcomes for the full cohort. In the study, 300 patients were randomized (PASCAL: n = 204; Mitr...

Key points of the DANPACE II study on atrial pacing and atrial fibrillation in sinus node dysfunction: 1. Minimizing atrial pacing in pacemakers doesn't prevent atrial fibrillation (AF): • 46% of patients regardless of pacing rate (40bpm or 60bpm) experienced an AF episode lasting over 6 minutes during 2 years. • No difference in AF rates across age, heart rhythm patterns, or prior AF history....

Major Trends: Independent Medical Board:  Cardiologists seek a new board separate from the ABIM due to concerns with MOC requirements. Scope of Practice Debates:  Tensions arise over advanced nurse practitioners performing complex procedures like TAVI. Work-Life Balance in Meetings:  Live meetings return, but concerns grow about FOMO and digital fatigue. AI in Cardiology:  ChatGPT and other tools...

Key Points of Coronary Artery Disease Studies in 2023: • ORBITA-2: Confirmed PCI's role in relieving angina symptoms for stable patients. • SELECT: Semaglutide (Ozempic) reduced cardiovascular events in overweight/obese patients with existing CVD. • Left Main CAD Revascularization: Guidelines downgraded PCI to less strong recommendation for low-risk patients. • ROMA-Women: Launched to study ge...

A quick rundown of the key developments: Trials: STEP-HFpEF CASTLE-HTx HEART FID DAPA-MI Policy and Guidelines: ESC cardiomyopathy guidelines Inflation Reduction Act FDA approvals: dapagliflozin and sotagliflozin Other Highlights: The world's second-living patient with end-stage heart failure received a genetically modified pig heart transplant but sadly died after 6 weeks due to transplant re...

Focus on Valves: TAVI vs. SAVR:  Long-term data showed mixed results. PARTNER 3 (Sapien 3 valve) benefits declined over time, while Evolut Low Risk (CoreValve, Evolut R/PRO) favoured TAVI. Experts advise caution in direct comparison. Aortic Regurgitation:  The ALIGN-AR trial demonstrated the success of the Trilogy valve for moderate-to-severe AR, with improved symptoms and quality of life. Ross Pr...

Key Highlights: Lodoco  is the first anti-inflammatory approved for reducing cardiovascular events in ASCVD patients. Bempedoic acid  offers an alternative for high-risk patients who can't tolerate statins. Semaglutide  has emerged as a powerful tool for reducing cardiovascular events in overweight or obese patients with pre-existing CVD. Recaticimab  is a long-acting injectable PCSK9 inhibito...

Key Points of Endovascular Procedures and Devices in 2023: FDA Actions: Lifted restrictions on paclitaxel-coated balloons and stents for PAD after updated data showed no increased mortality risk. Approved coverage of carotid artery stenting for Medicare beneficiaries with severe stenosis. Approved the LimFlow device for diverting blood flow in severe CLTI patients, offering limb salvage hope. Appr...

Heart Rhythm 2023: Innovations in Ablation, Devices, and Conduction System Pacing. Catheter Ablation and LAAO Advance: CASTLE-HTx:  Ablation for AF proved beneficial in patients with advanced heart failure, potentially paving the way for wider adoption. Pulsed-field ablation (PFA):  PULSED AF and ADVENT trials showed promise for novel PFA technologies like PulseSelect (Medtronic) and Farapulse (Bo...

Key Points: Multi-vessel coronary disease (MVD) in acute myocardial infarction (AMI) is still a difficult condition to manage. Complete revascularization improves outcomes for hemodynamically stable patients without any safety concerns. A personalized approach and evaluation by a team of heart specialists is recommended for making decisions in complex cases. More randomized trials are needed to be...

Key findings of the FRAIL-AF trial: * Switching from vitamin K antagonist (VKA) to non-vitamin K antagonist oral anticoagulant (NOAC) therapy was associated with an increased risk of major and clinically relevant bleeding (hazard ratio [HR] 1.69, 95% CI 1.23-2.32). * There was no difference in the risk of thromboembolic events between the two groups. * The trial included 1,330 patients with atrial...

Summary of the STEP-HFpEF trial 2023 published in Nature Medicine The STEP-HFpEF trial was a study of semaglutide in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). Semaglutide improved symptoms, physical limitations, exercise function, and reduced body weight in patients with HFpEF and obesity. The benefits of semaglutide were consistent across obesity ca...

Key points of the FIRE trial: The study was a randomized trial of complete revascularization vs. culprit-only revascularization in older patients (≥75 years of age) with myocardial infarction and multi-vessel disease. A total of 1445 patients were enrolled. The primary outcome was a composite of death, myocardial infarction, stroke, or any revascularization at 1 year. The key secondary outcome was...